Latest news
2024-01 – Q4 2023 Reporting
- After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down.
- Recruitment of patients in Australia remains very slow.
- Private Placement of 1,3 mil B-shares was completed and the proceeds of app. NOK 17 received. It was furthermore decided to do a Subsequent Offering of B-shares in early 2024.
2023-10 – Q3 2023 Reporting
- Screening of patients in New Zealand improved after visiting the clinical centres involved in SER150 CL-009 study.
- The broaden of inclusion criteria for recruitment of patients to the
SER150 CL-009 study is about to be approved by both health
authorities and the individual clinical centres. - The company raised app. NOK 17 M in a Private Placement.
2023-09 – Q2 2023 Reporting
- Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study.
- To facilitate enrolment, the entrance criteria will be revised for the SER150 CL-009 study based on feedback from investigators and serial blood collections will be removed from the protocol.
- The company has initiated a share issue through a private placement to raise funds to finalize the SER150 Cl-009 clinical study.
2023-06 – Investor Meeting in Copenhagen
Address:
Stokholmsgade 41
2100 Copenhagen E
June 21, 2023, at 15:00
Please reserve the date
2023-05 – Serodus ASA – Notice of General Meeting 2023
Norwegian VPS registred shareholders: VPS General Meeting
2023-05 – 2022 Annual Report
Serodus ASA – Publishes 2022 Annual Report
2023-04 – Q1 2023 Reporting
- Serodus has visited all clinical centers in Australia and New Zealand
- SER150/placebo dosing period has been prolonged from 3 to 6 months.
2023-02 – Q4 2022 Reporting
- New Zealand authorities approved the protocol with dosing of SER150 or placebo for six months.
- All clinical centers in Australia and New Zealand ready to initiate screening of patients in January for participation in study SER150 CL-009